Platelet Rich Plasma in Bleeding Peptic Ulcer
Platelet Rich Plasma in Bleeding Peptic Ulcer
The most common cause of acute upper gastrointestinal bleeding (UGIB) is non-variceal, where
 peptic ulcer bleeding (PUB) remains the single most common cause, accounting for 25% to 67%
 of the causes of non-variceal upper gastrointestinal bleeding (NVUGIB).

 Despite major advances in diagnostic and therapeutic tools, PUB remains a significant problem
 and an important cause of morbidity and mortality. Given the imperative therapeutic role of
 endoscopic management in achieving hemostasis in NVUGIB, new modalities to improve the
 current treatment strategies continue to be developed.

 Platelet-rich plasma (PRP) is a widely used throughout many fields of medicine for improving
 tissue regeneration. PRP contains a higher concentration of platelets than whole blood, and
 represents a pool of many growth-factors.
All patients were subjected to full history taking, complete clinical examination, laboratory
 investigations (complete blood count, liver and kidney function tests, coagulation profile),
 ECG and Upper GI endoscopy was performed within 24 hours of hospital admission after initial
 resuscitation of patients including blood transfusion if HB level ≤ 7g ∕ L.

 Stigmata of recent hemorrhage was defined according to the Forrest (F) classification (FIa-
 spurting hemorrhage, FIb- oozing hemorrhage, FIIa- non-bleeding visible vessel, FIIb-
 adherent clot, FIIc- flat pigmented spot and FIII- clean base ulcer).The size of an ulcer was
 classified as < 2 cm or ≥ 2cm.

 -  PRP or diluted epinephrine were injected in 1-2 ml by multiple injections into and
 circumferentially around the ulcer until bleeding stopped using a 25-G retractable,
 standard sclerotherapy needle.

 -  Group I was subjected to multiple injection of PRP (each 1-2 ml), while group II was
 subjected to epinephrine injections (each 1-2 ml of a 1:10.000 solution of epinephrine)
 .

 -  Hemostasis was achieved if bleeding stopped for at least 3 min of observation.
 Immediately after the endoscopic hemostasis, PPIs were infused at a standard regimen (40
 mg bolus of PPI once daily for 72 h) or at a high-dose regimen (loading dose of 80 mg on
 the first day followed by continuous infusion of 8 mg/h for 72 h), after the initial 72
 h, patients were switched to oral PPIs (20 mg twice daily) until discharge .

 PRP preparation method

 Under complete aseptic conditions the blood was drawn with the addition of anticoagulant such
 as citrate dextrose A to prevent platelet activation prior to its use.

 1.30-60 cc of patients' blood drawn at the time of treatment by venipuncture in acid citrate
 dextrose (acts as an anticoagulant) tubes 2. Do not chill the blood. 3. Centrifuge the blood
 using a 'soft' spin (1st centrifugation). 4. Transfer the supernatant plasma containing
 platelets into another sterile tube (without anticoagulant).

 5. Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate (2nd
 centrifugation).

 6. The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the
 tube, platelet pellets are formed.

 7. Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by
 gently shaking the tube.

 8.Thrombin (dose) was added to activate PRP
Inclusion Criteria:

 -  Patients who have a peptic ulcer with either actively bleeding or a non-bleeding
 visible vessel

 -  initial hemoglobin concentration of < 10 g/dL

 Exclusion Criteria:

 -  Patients with non-PUB, coagulopathy, bleeding disorders, anticoagulant therapy,
 cardiopulmonary compromise, hypertension, ischemic heart disease, arrhythmia, and
 patients who refused to participate in the study.